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Abstract
Background: In an effort to reduce the risk of breast cancer-related arm lymphedema, patients are commonly
advised to avoid heavy lifting, impacting activities of daily living and resistance exercise prescription. This advice
lacks evidence, with no prospective studies investigating arm volume changes after resistance exercise with heavy
loads in this population. The purpose of this study is to determine acute changes in arm volume after a session of
low- and heavy-load resistance exercise among women undergoing adjuvant chemotherapy for breast cancer at
risk for arm lymphedema.
Methods/Design: This is a randomized cross-over trial. Participants: Women receiving adjuvant chemotherapy for
breast cancer who have undergone axillary lymph node dissection will be recruited from rehabilitation centers in
the Copenhagen area. Intervention: Participants will be randomly assigned to engage in a low- (two sets of 15–20
repetition maximum) and heavy-load (three sets of 5–8 repetition maximum) upper-extremity resistance exercise
session with a one week wash-out period between sessions. Outcome: Changes in extracellular fluid (L-Dex score)
and arm volume (ml) will be assessed using bioimpedance spectroscopy and dual-energy x-ray absorptiometry,
respectively. Symptom severity related to arm lymphedema will be determined using a visual analogue scale (heaviness,
swelling, pain, tightness). Measurements will be taken immediately pre- and post-exercise, and 24- and 72-hours
post-exercise. Sample size: A sample size of 20 participants was calculated based on changes in L-Dex scores between
baseline and 72-hours post exercise sessions.
Discussion: Findings from this study are relevant for exercise prescription guidelines, as well as recommendations
regarding participating in activities of daily living for women following surgery for breast cancer and who may be at
risk of developing arm lymphedema.
Trial registration: Current Controlled Trials ISRCTN97332727. Registered 12 February 2015.
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Background
Approximately 20 % of breast cancer survivors develop
breast cancer-related arm lymphedema BCRL [1], with
an estimated 80 % of cases presenting within the first
two years of diagnosis [2]. It is associated with signifi-
cant impairments in gross and fine motor skills affect-
ing work, home and personal care functions, as well as
recreational and social relationships [3, 4]. While the
etiology of BCRL is unknown [1, 5], findings from a
systematic review and meta-analysis from 2013 [1] in-
cluding 72 studies demonstrate that axillary lymph
node dissection, more extensive breast surgery, radio-
therapy, chemotherapy, being overweight or obese and
physical inactivity are consistently associated with in-
creased BCRL risk [1].
Participation in resistance exercise has been found
to be a safe and effective exercise modality among
breast cancer survivors at risk of BCRL [6, 7], and is
associated with increases in lean muscle mass and
strength, which in turn positively effect physical func-
tion and ability. Furthermore, findings from a recent
meta-analysis [6] suggest that resistance exercise can
reduce the risk of BCRL versus control conditions
(OR = 0.53 (95 % CI 0.31–0.91); I2 = 0 %). However, the
current evidence-base is derived from studies that have
evaluated resistance exercise intensities considered to be
low to moderately heavy (60–80 % of 1 repetition max-
imum (RM) or 8–15 RM) [6, 7]. Yet, exercise science
literature indicates that heavy-load resistance exercise
(80–90 % 1RM or 5–8 RM) [8] is more effective than low-
to moderate-load resistance exercise in generating muscle
strength gains [9]. There is therefore a clear need for stud-
ies evaluating the safety of heavy-load resistance exercise
in the at-risk population [7].
In a novel study by Cormie et al. [10], which evalu-
ated the effect of low- and heavy-load resistance exer-
cise among a sample with BCRL, lymphedema status
and lymphedema symptoms remained stable immedi-
ately after exercise, and 24- and 72-hours after exercise,
irrespective of load. While these findings provide im-
portant information for women with BCRL, the pur-
pose of this study is to determine acute changes in
extracellular fluid, arm volume and associated lymph-
edema symptoms after a session of low- and heavy-load
resistance exercise in women at risk for BCRL. It is hy-
pothesized that no interlimb differences in extracellular
fluid, arm volume or lymphedema-associated symptom
severity will be observed over time or between resist-
ance exercise loads.
Design
This study is a randomized, cross-over trial (Table 1
here).
Table 1 Trial registration data
Trial registration data
Primary registry and trial
identify number
Current Controlled Trials ISRCTN97332727.
Date of registration in
primary registry
12 February 2015.
Secondary identifying
numbers
H-3-2014-147, 30-1430
Source of monetary or
material support
University Hospitals Centre for Health
Research, Copenhagen University Hospital
Rigshospitalet
Primary sponsor University Hospitals Centre for Health Research,
Copenhagen University Hospital Rigshospitalet
Secondary sponsor
Contact for public
queries
KB, MHS, PhD-stud. kibl30@hotmail.com, (45)
35347362, Blegdamsvej 9 (afsnit 9701), 2100
Copenhagen
Contract for scientific
queries
KB, MHS, PhD-stud. kibl30@hotmail.com, (45)
35347362, Blegdamsvej 9 (afsnit 9701), 2100
Copenhagen
Public title A trial to detect differences in arm volume
after low- and heavy-load resistance exercise
among patients receiving adjuvant
chemotherapy for breast cancer at risk
for arm lymphedema: Study Protocol
Scientific title A randomized cross-over trial to detect
differences in arm volume after low- and
heavy-load resistance exercise among patients
receiving adjuvant chemotherapy for breast
cancer at risk for arm lymphedema:
Study Protocol
Countries of
recruitment
Denmark
Health condition or
problem studied
Breast cancer-related arm lymphedema
Intervention Heavy vs low load resistance exercise for the
upper extremities
Key inclusion and
exclusion criteria
Inclusion criteria: > 18 years of age, unilateral
breast surgery, axillary node dissection,
undergoing adjuvant chemotherapy for breast
cancer
Exclusion criteria: Previously treated for breast
cancer, diagnosis of BCRL and/or currently
receiving treatment for BCRL, or having
conditions hampering resistance exercise of
the upper body, or having participated in
regular upper-body heavy resistance exercise
during the last month
Study type Interventional
Randomized cross-over, assessor blinded
Safety
Date of first enrolment 31-03-2015
Target sample size 40
Recruitment status Recruiting
Primary outcome Arm extracellular fluid (L-dex score) post-,
24- and 72 h post exercise
Key secondary
outcomes
Arm volume (ml) post-, 24- and 72 h post
exercise
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Methods
Participants / Recruitment
Twenty women allocated to adjuvant chemotherapy for
breast cancer consisting of three cycles of 3-weekly epiru-
bicin followed by three cyles of 3-weekly docetaxel will be
recruited from municipality lead rehabilitation centers in
the Copenhagen area and from a waiting list to the Body
and Cancer program [11, 12], at the University Hospitals
Center for Health Research (UCSF) at the Copenhagen
University Hospital, Rigshospitalet. All patients will be
screened for inclusion by health professionals (nurse or
physical therapist) at the respective centers. Potential par-
ticipants fulfilling inclusion criteria; over 18 years of age,
unilateral breast surgery, axillary node dissection, and ini-
tiating /undergoing adjuvant chemotherapy for breast
cancer (stage I - III) will be contacted during their first
three cycles of chemotherapy (Fig. 1). Patients previously
treated for breast cancer, with a diagnosis of BCRL and/or
currently receiving treatment for lymphedema, or having
conditions hampering resistance exercise of the upper
body, or having participated in regular (>1 × / week)
upper-body heavy resistance exercise during the last
month will be excluded.
Those fulfilling study criteria and expressing interest
in study participation will thereafter be screened for
BCRL by the first author after the third cycle of chemo-
therapy, using bioimpedance spectroscopy (BIS). Fur-
thermore, in accordance with common toxicity criteria
(CTC) v3.0 lymphedema criteria for the limb [13], pa-
tients will be visually inspected to detect differences in
signs of swelling between arms. Those presenting with
BCRL, defined as a lymphedema index (L-Dex) score of
10 or greater [14–16] (as assessed by BIS), and/or visual
signs of swelling (obscuration of anatomic architecture
or pitting edema) of the at-risk arm [13] will be referred
for treatment, and will not be included in the study.
Written and oral information regarding the study will
be delivered by the first author, as well as obtainment of
informed written consent.
Concealed randomization
Prior to the study, a computer-generated random se-
quence will be generated by an external researcher not
otherwise affiliated with the study, and concealed in
opaque envelopes. Group assignment will be disclosed
to the first author by telephone after study inclusion and
participation in the familiarization period. Participants
will be allocated using a 1:1 ratio to partake in either
low- or heavy-load resistance exercise first.
Exercise sessions
Participants will engage in a familiarization period, com-
prising of two training sessions up to one week apart, after
the third cycle of chemotherapy. Each session will start
with a 10- minute aerobic warm-up using a cross-trainer
(Glidex, Technogym®, Gamettola, Italy). During the first
familiarization session participants will be introduced to
four upper-body exercises (chest press, latissimus pull
down, triceps extension (Technogym®, Gamettola, Italy)
and biceps curl (free weights)) followed by a 1RM strength
test in each exercise. At the second familiarization session,
two sets of 10–15 RM will be performed and a new 1RM
strength test will be undertaken to ensure accuracy of sub-
sequent exercise prescription. Participants will engage in
the first experimental session after the first cycle of doce-
taxel (fourth chemotherapy), followed by a wash-out
period of 6 days. Two sets of 15–20 RM of each exercise
will be performed during low-load resistance exercise and
three sets of 5–8 RM during heavy-load. All sets will be
performed to muscle fatigue in sessions individually super-
vised by the first author (a physical therapist with experi-
ence in exercise prescription for women with breast
cancer) at training facilities located at Rigshospitalet.
Outcomes (pre- and post, 24- and 72-hours after resist-
ance exercise)
Measurements will be performed by medical technicians
with no knowledge of group (low- / high-load first) allo-
cation at the Department of Clinical Physiology and
Fig. 1 Study time line
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Nuclear Medicine at the Copenhagen University Hos-
pital, Rigshospitalet. Participants are advised to maintain
their normal activities during study participation. At all
assessment points, participants will be asked about their
physical activities, and any extraordinary activities will
be recorded.
Primary outcome
Extracellular fluid BIS (SFB7, Impedimed, Brisbane,
Australia) directly measures the impedance of extracel-
lular fluid and has a high reliability for detecting BCRL
[14, 16, 17] (intraclass correlation coefficient (ICC) =
0,99) [18]. Participants will be positioned in supine with
arms and legs slightly abducted from the trunk with
palms facing down. Utilizing the principle of equipoten-
tials, four single tab electrodes will be placed in a tetrapo-
lar arrangement [17]. Measurement electrodes will be
placed on the dorsum of the wrist midway between the
styloid processes, with current drive electrodes placed five
centimeters distally on the dorsal side over the third meta-
carpal of the hand, and approximately midway on the
third metatarsal on the dorsum of the foot [17, 19]. Each
limb will be measured at a range of frequencies using the
manufacturer’s software. The ratio of impedance between
the at-risk and non-affected limb will be calculated and
converted into a L-Dex score.
Secondary outcomes
Arm volume Dual energy x-ray absorptiometry (DXA)
(Lunar Prodigy Advanced Scanner, GE Healthcare,
Madison, WI) measures tissue composition using a three-
compartment model that is sensitive to changes in upper-
limb tissue composition [20, 21]. Using previously derived
densities for: fat (0.9 g/ml); lean mass (1.1 g/ml); bone
mineral content (BMC) (1.85 g/ml), the measured DXA
tissue weights will be transformed into estimated arm vol-
umes [20, 21].
Participants will be positioned on the scan-table, lying
supine with the arm separated from the trunk. If neces-
sary a Velcro band will be used over the breast to ensure
space between the arm and truncus. Each arm will be
scanned separately. Small animal software (Encore ver-
sion 14.10) will be used to analyze the scans as described
by Gjorup et al. [20]. Scans will be point typed where
soft tissue is marked as bone, whereafter regions of
interest (ROIs) will be drawn around the hand and the
arm on every scan (Fig. 2). All scans will be analyzed by
one examiner (last author) with experience in analyzing
DXA scans.
Subjective assessment of symptoms The severity of symp-
toms related to arm lymphedema including swelling,
heaviness, pain and tightness, will be monitored using a
visual analogue scale, whereby 0 represents no discomfort
and 10 is indicative of very severe discomfort [10].
Fig. 2 DXA regions of interest
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One year follow-up
Statistically, it is assumed that some of the participants
in the study will develop arm lymphedema. Furthermore,
previous studies have found a highly variable response to
resistance exercise [10, 22]. A one year exploratory, hy-
pothesis generating follow-up has been planned as it
provides an opportunity to determine how many partici-
pants develop arm lymphedema and whether individual
variability in response to the resistance exercise ses-
sions is related to subsequent lymphedema incidence.
Measurements will include 1RM strength in the four
resistance exercises, DXA, BIS and symptom severity
(VAS) as described, and a structured interview by the
first author to determine other known and theoretical
risk factors.
Blinding
All data collection and analysis will be conducted by
study personnel with no knowledge of group (low- /
high-load first) allocation.
Sample size and analytical plan
The sample size calculation is based on changes in L-Dex
scores between baseline and 72 h post-resistance exercise
sessions. From results of Cormie et al. [10] we hypothesize
the standard deviation in the distribution to be 1.9 units.
No published normative change scores exist for the at-risk
population, as well as no evidence regarding a threshold
for a clinically significant acute change. For patients with
BCRL a change score of 2L-Dex units is considered clinic-
ally relevant based on clinical experience. We believe that
an L-Dex of 2 units is too conservative in the at-risk popu-
lation, and have therefore set a threshold at 3L-Dex units.
Thus, if there is no difference between groups, then 18 pa-
tients are required to be 90 % sure that the limits of a
two-sided 90 % confidence interval will exclude a differ-
ence in means of more than 3.0. To allow for possible
drop-outs we plan to include 20 patients.
Data will be analyzed using the Statistical Package for
Social Sciences (SPSS) software (version 19) for Windows
(IBM SPSS, Chicago, IL). Analysis will include standard
descriptive statistics and both intention to treat and per-
protocol analysis will be performed. Using a generalized
estimating equations framework for continuous outcomes
to determine time (baseline, pre-, post, 24- and 72 h) and
intervention (low-/ heavy-load) effects, the interaction
between time and intervention will be considered [23].
Two-tailed p < 0.05 will be taken as evidence of statis-
tical significance.
Safety and ethical considerations
The treating oncologist will have the overall responsibil-
ity for the participants. All personal data will be treated
in accordance with existing rules and regulations.
A full body DXA scan utilizes weak x-rays and is not
considered dangerous [24]. In this study, since only arms
will be scanned the radiation dose is estimated to be
0.0001 mSv for both arms. Eight scans result in a total
dose of 0.0008 mSv, which is less than the background
radiation an average person is exposed to in one day in
Denmark.
As about 20 % of women treated for breast cancer de-
velop BCRL [1], it is expected that some of the partici-
pants in this study will develop BCRL. Participation in
this study involves regular assessment of the at-risk arm
during the study period, using some of the best technol-
ogy to date. This allows for early detection of BCRL,
which in turn would render a better prognosis, as early
detection is associated with a better outcome [4]. If par-
ticipants develop signs of swelling or an L-Dex score
persisting over one week during the familiarization or
experimental study period, they will be referred to the
treating oncologist for lymphedema treatment and will
be withdrawn from the study.
A completed SPIRIT checklist is included as Additional
file 1.
Discussion
Participating in resistance exercise during adjuvant chemo-
therapy for breast cancer has been associated with increases
in muscle strength [25–29], lean body mass [25, 28], and
self-esteem [25], and has been found to mitigate fatigue
and to maintain quality of life [29]. Furthermore, there is
evidence to suggest that resistance exercise might be asso-
ciated with a higher completion rate of planned chemo-
therapy [25]. Moreover, generalized edema characterized
by an increase in the size of the interstitial compartment
of extracellular fluid is a potential side effect to taxane-
based chemotherapy [30, 31]. Thus, swelling as a conse-
quence of increased fluid in addition to an impairment of
lymph fluid transport, could potentially contribute to
swelling of the at-risk arm. Hypothetically, this could be
thwarted by resistance exercise due to increased lymph
clearance likely through the effects of the muscle pump
[32, 33], lending additional rationale for instigating resist-
ance exercise during adjuvant chemotherapy.
To our knowledge, studies investigating the safety and
efficacy of resistance exercise in patients at risk for BCRL
have utilized low- to moderate-resistance exercise inten-
sities [6, 7], with only one cross-sectional study [11] inves-
tigating heavy-load resistance exercise. Indeed, in a paper
identifying the top 10 research questions related to phys-
ical activity and cancer survivorship, Courneya et al. [34]
highlighted the need for studies investigating safety and
optimal exercise prescription, and specifically the role of
vigorous-intensity activity, as important research areas [34].
The rational for utilizing heavy-load resistance exercise
is supported by exercise science literature that indicates
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that this higher training intensity can lead to additional
benefits as a dose–response relationship exists between
the load of resistance exercise and gains in muscular
structure and function [35, 36]. Furthermore, breast can-
cer survivors may suffer from losses of bone mass (par-
ticularly those on aromatase inhibitors), at least in part
as a result of the catabolic effects of treatment. Resist-
ance exercise interventions with lower loads have not
yielded significant training effects on bone mineral dens-
ity [27, 37]. It has been postulated that the absence of a
measurable effect on bone mass density is related to the
adaptive nature of bone that requires heavier loads [37],
as heavy-load resistance exercise has been identified as
an osteogenic exercise modality in women without can-
cer [38]. Thus, establishing the safety of heavy-load re-
sistance exercise is prudent and of significance for the
breast cancer population.
No standardized measurement method exists to diag-
nose or monitor BCRL [1, 20, 21], with a variety of tech-
niques and definitions used. Early BCRL is characterized
by an increase in extracellular fluid. Indirect measure-
ment methods such as circumference, water displace-
ment, and perometry measure volume of the entire limb
to detect small changes in extracellular fluid which ac-
counts for approximately 25 % of the total limb, and do
not differentiate between tissue types [5, 18]. In contrast,
BIS directly measures lymph fluid change by measuring
the impedance to a low level electrical current allowing
for a sensitive [21, 39] and reliable measurement method
to detect extracellular fluid changes among at-risk breast
cancer survivors [39]. Furthermore, BIS is fast and easy
to administer, and as impedance measures are reported
as an L-Dex value, inherent volume differences associated
with hand dominance are taken into account [5, 39]. How-
ever, BIS loses its sensitivity to monitor BCRL over time
as lymphedema progresses into later stages, whereby the
excess extracellular fluid initially characterizing BCRL is
replaced with adipose tissue [5, 21].
DXA is another measurement method that can differen-
tiate between tissue types giving an estimate of BMC, fat
mass and lean mass where the lean mass component in-
cludes extracellular fluid [20, 21, 40]. DXA has been found
to be sensitive to changes in tissue composition, making it
an ideal measurement method to monitor BCRL over time
as fluid components are replaced with adipose tissue. Fur-
thermore, DXA allows for analysis of separate regions of
the arm, of potential clinical importance for patients
where swelling is confined to a specific region of the arm
or hand [20, 21, 40, 41]. In this study we scan the arms
separately and use software with a high resolution allow-
ing for more precise definition of ROIs and the possibility
to define bone and soft tissue manually as described by
Gjorup et al., with a low inter-rater variation (ICC ≥,9990)
[20]. To the authors’ knowledge, this is the first time that
DXA, with this software, will be used to detect volume
changes in the BCRL at-risk population adding new in-
sights into the application of this measurement method.
This exploratory study utilizes a cross-over design to de-
termine acute changes in extracellular fluid and arm vol-
ume. This design lends more statistical power, with the
practical advantage of a smaller sample size, as between-
patient variation is inherently eliminated [42], providing a
framework for an efficient comparison between the two
resistance exercise loads. However, this study can only
provide us with information regarding extracellular fluid
and arm volume changes after one resistance exercise ses-
sion, limiting the generalizability to repeated resistance ex-
ercise training and long-term effects on arm volume.
Nonetheless, this study can lend initial evidence regarding
the safety of heavy-load lifting and can help guide future
studies and optimal exercise prescription.
Finally, women at risk for BCRL still receive risk reduc-
tion advice including avoiding heavy lifting [43, 44]. This
advice can lead to women being apprehensive about lifting
heavy loads with consequences for daily living (e.g., not
lifting children, groceries, etc.). However, this advice is not
based on research and knowledge gained from this study
can provide a preliminary evidence base for guiding risk
reduction practices involving intermittent heavy-load ac-
tivity necessary for daily living.
Additional file
Additional file 1: SPIRIT checklist. (DOC 121 kb)
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